While Trevor Martin was an undergraduate at Princeton, he decided on a whim to take a class called Integrated Science, a course dedicated to encouraging students gifted in physics, math, or computer science to pursue an academic focus in biology. Unbeknownst to him, this class would end up being the catalyst that led him to his successful career as a biotech entrepreneur. After receiving his PhD from Stanford in 2017, Trevor founded Mammoth Biosciences, the platform revolutionizing CRISPR-based synthetic biology products across therapeutics and diagnostics, with the ultimate mission of finding permanent cures for diseases. Trevor shares his favorite mantra: “Let others say no,” how biotechs need to strike the right balance between commercializing their products and researching the next generation of products, and why Mammoth’s go-to-market strategy facilitates the flywheel needed to build a generational business.